Antiproliferative activities of parthenolide and golden feverfew extract against three human cancer cell lines

Journal of Medicinal Food

Volumn 9, Issue 1, 2006, Pages 55-61

  Wu, Changqing ^a   Chen, Feng ^a   Rushing, James W ^a   Wang, Xi ^a   Kim, Hyun Jin ^a   Huang, George ^a   Haley Zitlin, Vivian ^a   He, Guoqing ^b  

^a CLEMSON UNIVERSITY   (United States)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Antiproliferative activity; Apigenin; Breast cancer; Feverfew; Flavonoid; Hs605T; Luteolin; MCF 7; Parthenolide; SiHa; Tanacetum parthenium

Indexed keywords

APIGENIN; CAMPHOR; LUTEOLIN; PARTHENOLIDE; SESQUITERPENE LACTONE; TANACETUM PARTHENIUM EXTRACT; NONSTEROID ANTIINFLAMMATORY AGENT; PLANT EXTRACT; SESQUITERPENE;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRAIN MCF 7; DRUG ACTIVITY; DRUG POTENTIATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; MIGRAINE; PRIORITY JOURNAL; TANACETUM PARTHENIUM; TRADITIONAL MEDICINE; BREAST TUMOR; CELL DIVISION; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; NEOPLASM; PATHOLOGY; TUMOR CELL LINE; UTERINE CERVIX TUMOR;

DRYOBALANOPS; TANACETUM PARTHENIUM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APIGENIN; BREAST NEOPLASMS; CAMPHOR; CELL DIVISION; CELL LINE, TUMOR; DRUG SYNERGISM; FEMALE; HUMANS; LUTEOLIN; NEOPLASMS; PLANT EXTRACTS; SESQUITERPENES; TANACETUM PARTHENIUM; UTERINE CERVICAL NEOPLASMS;

EID: 33745501042     PISSN: 1096620X     EISSN: None     Source Type: Journal    
DOI: 10.1089/jmf.2006.9.55     Document Type: Article

References (34)

1. Marles RJ, Pazos-Sanou L, Compadre CM, Pezzuto JM, Bloszyk E, Arnason T: Sesquiterpene lactones revisited. In: Phytochemistry of Medicinal Plants (Arnason JT, Mat R, Romeo JT, eds.), Plenum Press, New York, 1995, pp. 333-356.
2. Govindachari TR, Joshi BS, Kamat VN: Revised structure of parthenolide. Tetrahedron Lett 1964;52:3927-3933.
3. Groenewegen WA, Heptinstall SA: Comparison of the effects of an extract of feverfew and parthenolide, a component of feverfew, on human platelet activity in vitro. J Pharm Pharmacol 1990;42:553-557.
4. Groenewegen WA, Knight DW, Heptinstall S: Progress in the medicinal chemistry of the herb feverfew. In: Progress in Medicinal Chemistry, Vol. 29 (Ellis GP, Luscombe DK, eds.), Elsevier Science Publishers, New York, 1992, pp. 217-238.
5. Hewlett MJ, Begley MJ, Groenewegen WA, Heptinstall S, Knight DW, May J, Salan U, Toplis D: Sesquiterpene lactones from feverfew, Tanacetum parthenium: isolation, structural revision, activity against human blood platelet function and implications for migraine therapy. J Chem Soc Perkin Trans 1996;1:1979-1986.
6. Mittra S, Datta A, Singh SK, Singh A: 5-Hydroxytryptamine-inhibiting property of feverfew: role of parthenolide content. Acta Pharmacol Sin 2000;21:1106-1114.
7. Reuter U, Chiarugi A, Bolay H, Moskowtz MA: Nuclear factor-κB as a molecular target for migraine therapy. Ann Neurol 2002;51:507-516.
8. Johnson ES, Kadam NP, Hylands DM, Hylands PJ: Efficacy of feverfew as prophylactic treatment of migraine. Br Med J 1985;291:569-573.
9. Murphy JJ, Heptinstall S, Mitchell JRA: Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 1988;2:189-192.
10. Palevitch D, Earon G, Carasso R: Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: a double-blind placebo-controlled study. Phytother Res 1997;11:508-511.
11. Hay AJ, Hamburger M, Hostettmann K, Hoult JR: Toxic inhibition of smooth muscle contractility by plant-derived sesquiterpenes caused by their chemically reactive alpha-methylenebutyrolactone functions. Br J Pharmacol 1994;112:9-12.
12. Picman AK: Biological activities of sesquiterpene lactones. Biochem Syst Ecol 1986;14:255-281.
13. Lee K-H, Huang E-S, Piantadosi C, Pagano JS, Geissman TA: Cytotoxicity of sesquiterpene lactones. Cancer Res 1971;31:1649-1654.
14. Hoffman JJ, Torrance SJ, Wiedhopf RM, Cole JR: Cytotoxic agents from Michelia champaca and Talauma avata: parthenolide and costunolide. J Pharm Sci 1977;66:883-884.
15. Ross JJ, Arnason JT, Birnboim HC: Low concentrations of the feverfew component parthenolide inhibit in vitro growth of tumor lines in a cytostatic fashion. Planta Med 1999;65:126-129.
16. Wen J, You K-R, Lee S-Y, Song C-H, Kim D-G: Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide. J Biol Chem 2002;277:38954-38964.
17. Hall IH, Lee K-H, Mar EC, Starnes CO, Waddell TG: Antitumor agents. 21. A proposed mechanism for inhibition of cancer growth by tenulin and helenalin and related cyclopentenones. J Med Chem 1977;20:333-337.
18. Hall IH, Lee K-H, Starnes CO, Eigebaly SA, Ibuka T, Wu Y-S, Kimura T, Haruna M: Antitumor agents. XXX: Evaluation of α-methylene-γ- lactone-containing agents for inhibition of tumor growth, respiration, and nucleic acid synthesis. J Pharm Sci 1978;67:1235-1239.
19. Lee K-H, Hall IH, Mar EC, Starnes CO, ElGebaly SA, Waddell TG, Hadgraft RI, Ruffner CG, Weidner I: Sesquiterpene antitumor agents: inhibitors of cellular metabolism. Science 1977;196:533-536.k
20. Woynarowski JM, Konopa J: Inhibition of DNA biosynthesis in HeLa cells by cytotoxic and antitumor sesquiterpene lactones. Mol Pharmacol 1981;19:97-102.
21. Li-Weber M, Giaisi M, Baumann S, Treiber MK, Krammer PH: The anti-inflammatory sesquiterpene lactone parthenolide suppresses CD95-mediated activation-induced-cell-death in T-cells. Cell Death Differ 2002;9:1256-1265.
22. Hehner SP, Hofmann TG, Droge W, Schmitz ML: The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-κB by targeting the IκB kinase complex. J Immunol 1999;163:5617-5623.
23. Patel NM, Nozaki S, Shortle NH, Bhat-Nakshatri P, Newton TR, Rice S, Gelfanov V, Boswell SH, Goulet RJ, Siege GW, Nakshatri H: Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide. Oncogene 2000;19:4159-4169.
24. 3-induced differentiation of human leukaemia HL-60 cells into monocytes by parthenolide via inhibition of NF-κB activity. Br J Pharmacol 2002;135:1235-1244.
25. Bork PM, Schmitz LM, Kuhnt M, Escher C, Heinrich M: Sesquiterpene lactone containing Mexican Indian medicinal plants and pure sesquiterpene lactones as potent inhibitors of transcription factor NF-κB. FEBS Lett 1997;402:85-90.
26. Groenewegen WA, Knight DW, Heptinstall S: Compounds extracted from feverfew that have anti-secretory activity contain an α-methylene butyrolactone unit. J Pharm Pharmacol 1986;38:709-712.
27. Pugh WJ, Sambo K: Prostaglandin synthetase inhibitors in feverfew. J Pharm Pharmacol 1988;40:743-745.
28. Williams CA, Harborne JB, Geiger H, Hoult JRS: The flavonoids of Tanacetum parthenium and T. vulgare and their anti-inflammatory properties. Phytochemistry 1999;51:417-423.
29. Lepley DM, Li B, Birt DF, Peling JC: The chemopreventive flavonoid apigenin induces G2/M arrest in keratinocytes. Carcinogenesis 1996;17:2367-2375.
30. McVean M, Xiao H, Isobe K-I, Pelling JC: Increase in wild-type p53 stability and transactivational activity by the chemopreventive agent apigenin in keratinocytes. Carcinogenesis 2000;21:633-639.
31. Han D-H, Yamada K, Tachibana H: Inhibition of environmental estrogen-induced proliferation of human breast carcinoma MCF-7 cells by flavonoids. In Vitro Cell Dev Biol 2001;37:275-282.
32. Pettit GR, Hoard MS, Doubek DL, Schmidt JM, Pettit RK, Tackett LP, Chapius J-C: Antineoplastic agents 338: The cancer cell growth inhibitory constituents of Terminalia arjuna (Combretaceae). J Ethnopharmacol 1996;53:57-63.
33. Piela-Smith TH, Liu X: Feverfew extracts and the sesquiterpene lactone parthenolide inhibit intercellular adhesion molecule-1 expression in human synovial fibroblasts. Cell Immunol 2001;209:89-96.
34. Ramanathan L, Gray WG: Identification and characterization of a phytoestrogen-specific gene from the MCF-7 human breast cancer cell. Toxicol Applied Pharmacol 2003;191:107-117.